ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
A. Maiolino,
P. Moreau,
M. Dimopoulos,
J. Mikhael,
K. Yong,
M. Capra,
T. Facon,
R. Hajek,
I. Spicka,
M. Risse,
G. Asset,
S. Macé,
T. Martin
Affiliations
A. Maiolino
Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, RJ, Brazil
P. Moreau
University Hospital Hôtel-Dieu, Nantes, France
M. Dimopoulos
The National and Kapodistrian University of Athens, Athens, Greece
J. Mikhael
Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, United States
K. Yong
University College Hospital, London, United Kingdom
M. Capra
Hospital Mãe de Deus, Porto Alegre, RS, Brazil
T. Facon
Lille University Hospital, Lille, France
R. Hajek
University Hospital Ostrava, Ostrava, Czech Republic
I. Spicka
Charles University in Prague, Prague, Czech Republic
M. Risse
Sanofi R&D, Vitry/Alfortville, France
G. Asset
Sanofi R&D, Chilly-Mazarin, France
S. Macé
Sanofi R&D, Vitry/Alfortville, France
T. Martin
University of California at San Francisco, San Francisco, United States
